Modification of myocardial substrate use as a therapy for heart failure (Q36577562)

15 August 2017

1 reference

title

Modification of myocardial substrate use as a therapy for heart failure (English)

1 reference

15 August 2017

0 references

Khalid Abozguia

1

1 reference

15 August 2017

Kieran Clarke

series ordinal

2

1 reference

15 August 2017

Leong Lee

series ordinal

3

1 reference

15 August 2017

Michael Frenneaux

series ordinal

4

1 reference

15 August 2017

1 September 2006

1 reference

Nature Clinical Practice Cardiovascular Medicine

15 August 2017

1 reference

15 August 2017

3

1 reference

15 August 2017

9

1 reference

15 August 2017

490-498

1 reference

The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase

15 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

Perhexiline maleate and peripheral neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

Human myocardial adenosine triphosphatase activities in health and heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

Human myocardial ATP content and in vivo contractile function

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

Absolute concentrations of high-energy phosphate metabolites in normal, hypertrophied, and failing human myocardium measured noninvasively with (31)P-SLOOP magnetic resonance spectroscopy

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

Progressive loss of myocardial ATP due to a loss of total purines during the development of heart failure in dogs: a compensatory role for the parallel loss of creatine

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

ATP flux through creatine kinase in the normal, stressed, and failing human heart

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

1 reference

7 January 2021

Proton magnetic resonance spectroscopy can detect creatine depletion associated with the progression of heart failure in cardiomyopathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

Subcellular creatine kinase alterations. Implications in heart failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

Detection of low phosphocreatine to ATP ratio in failing hypertrophied human myocardium by 31P magnetic resonance spectroscopy

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

Nitric oxide inhibits creatine kinase and regulates rat heart contractile reserve

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

The effect of dietary creatine supplementation on skeletal muscle metabolism in congestive heart failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

Transcriptional coactivator PGC-1 alpha controls the energy state and contractile function of cardiac muscle.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

Myocardial substrate metabolism in the normal and failing heart

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

Effects of long-term pressure overload on regional myocardial glucose and free fatty acid uptake in rats. A quantitative autoradiographic study

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

The development of myocardial insulin resistance in conscious dogs with advanced dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

Free fatty acid kinetics and oxidation in congestive heart failure.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

13C imaging-a new diagnostic platform.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

Triacylglycerol metabolism in hypoxic, glucose-deprived rat cardiomyocytes

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

Myocardial substrate metabolism influences left ventricular energetics in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

Increased uncoupling proteins and decreased efficiency in palmitate-perfused hyperthyroid rat heart

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

Uncoupling protein 3 as a mitochondrial fatty acid anion exporter

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

Uncoupling proteins in human heart

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

Effect of free fatty acids on myocardial function and metabolism in the ischemic dog heart

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

Haemodynamic effects of intracoronary pyruvate in patients with congestive heart failure: an open study

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

Effects of trimetazidine on left ventricular function in patients with type 2 diabetes and heart failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

Ranolazine increases active pyruvate dehydrogenase in perfused normoxic rat hearts: evidence for an indirect mechanism

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

Short-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

Relationship between QT interval and cardiovascular risk factors in healthy young subjects

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

Carnitine palmitoyl transferase-I inhibition prevents ventricular remodeling and delays decompensation in pacing-induced heart failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

Cardiac Hypertrophy in the Dog and Rat Induced by Oxfenicine, an Agent Which Modifies Muscle Metabolism

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

Biochemical mechanisms of oxfenicine cardiotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

Regulation of glucose utilization during the inhibition of fatty acid oxidation in rat myocytes

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

Additive hypoglycemic effects of drugs that modify free-fatty acid metabolism by different mechanisms in rats with streptozocin-induced diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

Modification of left ventricular hypertrophy by chronic etomixir treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

Response of isolated working hearts to fatty acids and carnitine palmitoyltransferase I inhibition during reduction of coronary flow in acutely and chronically diabetic rats

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

First clinical trial with etomoxir in patients with chronic congestive heart failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

Selective versus nonselective beta-adrenergic receptor blockade in chronic heart failure: differential effects on myocardial energy substrate utilization

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

Direct evidence that perhexiline modifies myocardial substrate utilization from fatty acids to lactate

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

Effect of perhexiline and oxfenicine on myocardial function and metabolism during low-flow ischemia/reperfusion in the isolated rat heart

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

Perhexiline maleate in the treatment of severe angina pectoris

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

Impaired oxidation of debrisoquine in patients with perhexiline liver injury

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

Perhexiline maleate treatment for severe angina pectoris--correlations with pharmacokinetics

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

Effects of perhexiline maleate on coronary flow distribution in the ischemic canine myocardium

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0583

7 January 2021

Identifiers

DOI

10.1038/NCPCARDIO0583

1 reference

15 August 2017

1 reference